This pilot study aimed to evaluate domperidone in the treatment of Chinese patients with functional dyspepsia (FD) diagnosed according to Rome IV criteria, including identification of FD subtypes that potentially respond better to domperidone.This study was conducted at hospitals in China from Aug 2018 to Jul 2020. The study consisted of a 1-week screening phase and a 2-week double-blind treatment phase. Participants were randomized to domperidone 10 mg or matching placebo tablets three times daily for 14 days. The primary endpoint was overall treatment effect (OTE) response rate after 2 weeks of therapy.The study enrolled 160 patients, 80 in each group. The OTE response rate after 2 weeks therapy was numerically higher for domperidone (60.7%) compared with placebo (46.0%) (relative risk [RR], 1.318; 95% confidence interval [CI], 0.972-1.787). The OTE response rates after 2 weeks by FD subtype for domperidone and placebo were 60.3% vs 54.9% for postprandial distress syndrome (PDS) (RR, 1.098; 95% CI, 0.750-1.607) and 60.6% vs 35.2% for overlapping PDS-epigastric pain syndrome (EPS) (RR, 1.722; 95% CI, 0.995-2.980). Adverse events were reported by seven patients in the domperidone group and twelve patients in the placebo group. None of the adverse events in the domperidone group were serious or unexpected.Domperidone showed a positive pattern on OTE response rates after 2 weeks therapy compared to placebo in patients with FD as well as in subtypes of PDS and overlapping PDS-EPS. No new safety signal was observed. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.